Citation: | Ya-Ling Zhu, Lei-Lei Meng, Jin-Hu Ma, Xin Yuan, Shu-Wen Chen, Xin-Rui Yi, Xin-Yu Li, Yi Wang, Yun-Shu Tang, Min Xue, Mei-Zi Zhu, Jin Peng, Xue-Jin Lu, Jian-Zhen Huang, Zi-Chen Song, Chong Wu, Ke-Zhong Zheng, Qing-Qing Dai, Fan Huang, Hao-Shu Fang. Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease. Zoological Research, 2024, 45(1): 79-94. doi: 10.24272/j.issn.2095-8137.2023.022 |
[1] |
Abuín JM, Pichel JC, Pena TF, et al. 2015. BigBWA: approaching the burrows-wheeler aligner to big data technologies.
|
[2] |
Becares N, Gage MC, Voisin M, et al. 2019. Impaired LXRα phosphorylation attenuates progression of fatty liver disease.
|
[3] |
Brunt EM, Kleiner DE, Wilson LA, et al. 2011. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.
|
[4] |
Dobin A, Davis CA, Schlesinger F, et al. 2013. STAR: ultrafast universal RNA-seq aligner.
|
[5] |
Dobrzyn P, Dobrzyn A, Miyazaki M, et al. 2004. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proceedings of the National Academy of Sciences of the United States of America, 101(17): 6409−6414.
|
[6] |
Dörr D, Obermayer B, Weiner JM, et al. 2022. C/EBPβ regulates lipid metabolism and Pparg isoform 2 expression in alveolar macrophages.
|
[7] |
Feinberg AP. 2007. Phenotypic plasticity and the epigenetics of human disease.
|
[8] |
Feng S, Reuss L, Wang Y. 2016. Potential of natural products in the inhibition of adipogenesis through regulation of PPARγ expression and/or its transcriptional activity.
|
[9] |
Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. 2018. Mechanisms of NAFLD development and therapeutic strategies.
|
[10] |
Hsieh WC, Sutter BM, Ruess H, et al. 2022. Glucose starvation induces a switch in the histone acetylome for activation of gluconeogenic and fat metabolism genes.
|
[11] |
Hu MJ, Long M, Dai RJ. 2022. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3.
|
[12] |
Jin CJ, Engstler AJ, Ziegenhardt D, et al. 2017. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice.
|
[13] |
Kim E, Lee JH, Ntambi JM, et al. 2011. Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro. European Journal of Pharmacology, 672(1–3): 38–44.
|
[14] |
Klepp TD, Sloan ME, Soundararajan S, et al. 2022. Elevated stearoyl-CoA desaturase 1 activity is associated with alcohol-associated liver disease.
|
[15] |
Lambert SA, Jolma A, Campitelli LF, et al. 2018. The human transcription factors.
|
[16] |
Li H, Handsaker B, Wysoker A, et al. 2009. The sequence alignment/map format and SAMtools.
|
[17] |
Li XZ, Yuan BC, Lu M, et al. 2021. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression.
|
[18] |
Liang N, Damdimopoulos A, Goñi S, et al. 2019. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.
|
[19] |
Liu Y, Jiang L, Sun CX, et al. 2018. Insulin/snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis.
|
[20] |
Love MI, Huber W, Anders S. 2014. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2.
|
[21] |
Marzi SJ, Leung SK, Ribarska T, et al. 2018. A histone acetylome-wide association study of Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex.
|
[22] |
Meng LL, Song ZC, Liu AD, et al. 2021. Effects of lipopolysaccharide-binding protein (LBP) single nucleotide polymorphism (SNP) in infections, inflammatory diseases, metabolic disorders and cancers.
|
[23] |
Moreno-Navarrete JM, Escoté X, Ortega F, et al. 2015. Lipopolysaccharide binding protein is an adipokine involved in the resilience of the mouse adipocyte to inflammation.
|
[24] |
Moseti D, Regassa A, Kim WK. 2016. Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules.
|
[25] |
Nien HC, Sheu JC, Chi YC, et al. 2018. One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis.
|
[26] |
Ntambi JM, Miyazaki M, Stoehr JP, et al. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proceedings of the National Academy of Sciences of the United States of America, 99(17): 11482−11486.
|
[27] |
Ospelt C. 2022. A brief history of epigenetics.
|
[28] |
Pfalzgraff A, Weindl G. 2019. Intracellular lipopolysaccharide sensing as a potential therapeutic target for sepsis.
|
[29] |
Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features.
|
[30] |
Rada-Iglesias A, Bajpai R, Swigut T, et al. 2011. A unique chromatin signature uncovers early developmental enhancers in humans.
|
[31] |
Samuel VT, Shulman GI. 2018. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases.
|
[32] |
Sewe SO, Silva G, Sicat P, et al. 2022. Trimming and validation of illumina short reads using trimmomatic, trinity assembly, and assessment of RNA-seq data. In: Edwards D. Plant Bioinformatics: Methods and Protocols. New York: Springer, 211–232.
|
[33] |
Smith E, Shilatifard A. 2014. Enhancer biology and enhanceropathies. Nature Structural & Molecular Biology, 21(3): 210−219.
|
[34] |
Soneson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences.
|
[35] |
Song ZC, Meng LL, He ZX, et al. 2021. LBP protects hepatocyte mitochondrial function via the PPAR-CYP4A2 signaling pathway in a rat sepsis model.
|
[36] |
Sun C, Fan JG, Qiao L. 2015. Potential epigenetic mechanism in non-alcoholic fatty liver disease. International Journal of Molecular Sciences, 16(3): 5161−5179.
|
[37] |
Sun L, Yu ZJ, Ye XW, et al. 2010. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese.
|
[38] |
Szklarczyk D, Morris JH, Cook H, et al. 2017. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.
|
[39] |
Takagi H, Tamura I, Fujimura T, et al. 2022. Transcriptional coactivator PGC-1α contributes to decidualization by forming a histone-modifying complex with C/EBPβ and p300.
|
[40] |
Takahashi JS, Kumar V, Nakashe P, et al. 2015. ChIP-seq and RNA-seq methods to study circadian control of transcription in mammals. Methods in Enzymology, 551: 285−321.
|
[41] |
Takeuchi F, Yanai K, Inomata H, et al. 2007. Search of type 2 diabetes susceptibility gene on chromosome 20q.
|
[42] |
Tamura I, Maekawa R, Jozaki K, et al. 2021. Transcription factor C/EBPβ induces genome-wide H3K27ac and upregulates gene expression during decidualization of human endometrial stromal cells.
|
[43] |
Villar D, Berthelot C, Aldridge S, et al. 2015. Enhancer evolution across 20 mammalian species.
|
[44] |
Whyte WA, Orlando DA, Hnisz D, et al. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes.
|
[45] |
Xi Y, Shen WJ, Ma LL, et al. 2016. HMGA2 promotes adipogenesis by activating C/EBPβ-mediated expression of PPARγ.
|
[46] |
Yang X, Sun DT, Xiang H, et al. 2021. Hepatocyte SH3RF2 deficiency is a key aggravator for NAFLD.
|
[47] |
Younossi Z, Tacke F, Arrese M, et al. 2019. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
|
[48] |
Youssefian L, Vahidnezhad H, Saeidian AH, et al. 2019. Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations.
|
[49] |
Yu Y, Cai JJ, She ZG, et al. 2019. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases.
|
[50] |
Zhang N, Wang YL, Zhang JL, et al. 2020. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1.
|
[51] |
Zhang Y, Liu T, Meyer CA, et al. 2008. Model-based analysis of ChIP-seq (MACS).
|
[52] |
Zhao N, Zhang XX, Ding JJ, et al. 2022a. SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface.
|
[53] |
Zhao S, Zhang XR, Li HT. 2018. Beyond histone acetylation—writing and erasing histone acylations.
|
[54] |
Zhao YC, Gao LC, Jiang CL, et al. 2022b. The transcription factor zinc fingers and homeoboxes 2 alleviates NASH by transcriptional activation of phosphatase and tensin homolog.
|
[55] |
Zheng RB, Wan CX, Mei SL, et al. 2019. Cistrome data browser: expanded datasets and new tools for gene regulatory analysis.
|
[56] |
Zhou Z, Xu MJ, Gao B. 2016. Hepatocytes: a key cell type for innate immunity. Cellular & Molecular Immunology, 13(3): 301−315.
|
[57] |
Zhu YL, Zeng QJ, Li F, et al. 2021. Dysregulated H3K27 acetylation is implicated in fatty liver hemorrhagic syndrome in chickens.
|
![]() |
![]() |